Zacks Research Forecasts Reduced Earnings for Haemonetics

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Zacks Research lowered their Q3 2027 earnings per share estimates for shares of Haemonetics in a research note issued to investors on Wednesday, January 29th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings per share of $1.30 for the quarter, down from their prior estimate of $1.31. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. During the same period in the prior year, the firm posted $0.99 EPS. The company’s revenue was up 8.6% on a year-over-year basis.

A number of other research firms also recently issued reports on HAE. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research report on Friday, November 8th. Barrington Research reiterated an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a report on Wednesday, December 4th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 price target on shares of Haemonetics in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Stock Down 0.8 %

Shares of NYSE HAE opened at $68.90 on Friday. The stock has a market capitalization of $3.46 billion, a PE ratio of 28.59, a P/E/G ratio of 1.06 and a beta of 0.41. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The firm has a fifty day moving average of $78.94 and a 200-day moving average of $79.38. Haemonetics has a 52-week low of $67.26 and a 52-week high of $97.97.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Envestnet Asset Management Inc. lifted its holdings in Haemonetics by 15.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 41,712 shares of the medical instruments supplier’s stock worth $3,451,000 after buying an additional 5,556 shares in the last quarter. Creative Planning acquired a new stake in shares of Haemonetics during the second quarter valued at about $368,000. Quarry LP acquired a new position in shares of Haemonetics in the second quarter worth about $39,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Haemonetics in the second quarter worth about $140,000. Finally, Central Pacific Bank Trust Division boosted its holdings in Haemonetics by 31.1% in the third quarter. Central Pacific Bank Trust Division now owns 2,765 shares of the medical instruments supplier’s stock valued at $222,000 after purchasing an additional 656 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.